---

Cancer Drugs Fund

Answer

Details of the drugs removed from the national Cancer Drugs Fund (CDF) list following re-prioritisation are shown in tables 1 and 2. The latest version of the list is available on NHS England’s website at: www.england.nhs.uk/ourwork/pe/cdf/. A copy is attached.

Table 1: Confirmation of previously notified drugs and indications delisted on 12 March 2015
Drug	Indication removed
Aflibercept	2nd line in combination with irinotecan-based combination chemotherapy for metastatic colorectal cancer
Bendamustine	Treatment of patients with indolent non-Hodgkin’s lymphoma who are refractory to rituximab
Bevacizumab	1st line in combination with oxaliplatin–based combination chemotherapy for metastatic colorectal cancer
Bevacizumab	1st line in combination with irinotecan–based combination chemotherapy for metastatic colorectal cancer
Bevacizumab	1st line in combination with single agent fluoropyrimidine–based chemotherapy for metastatic colorectal cancer.
Bevacizumab	In combination with carboplatin and gemcitabine chemotherapy for recurrent platinum sensitive ovarian cancer
Bortezomib	Re-treatment in patients with relapsed myeloma
Bortezomib	Treatment of patients with relapsed Waldenstrom’s macroglobulinaemia
Bortezomib	Treatment of patients with relapsed mantle cell lymphoma
Bosutinib	Treatment of blast phase chronic myeloid leukaemia
Cetuximab	2nd line in combination with irinotecan chemotherapy for metastatic colorectal cancer in patients with RAS wild type (non-mutated) tumours
Dasatinib	Treatment of the lymphoid blast phase of chronic myeloid leukaemia
Everolimus	Treatment of progressive unresectable or metastatic well differentiated neuroendocrine tumour of the pancreas
Lapatinib	In combination with capecitabine chemotherapy for HER-2 receptor positive locally advanced or metastatic breast cancer
Ofatumumab	Treatment of relapsed or refractory chronic lymphatic leukaemia
Pazopanib	Treatment of previously treated metastatic non-adipocytic soft tissue sarcomas
Pegylated liposomal doxorubicin	1st or 2nd line chemotherapy of angiosarcoma
Pegylated liposomal doxorubicin	Chemotherapy of primary malignant sarcomas of the heart and great vessels
Source: National Cancer Drugs Fund List Ver 6.0

Table 2: Confirmation of previously notified drugs and indications delisted on 4 November 2015
Drug	Indication removed
Albumin bound Paclitaxel	First line treatment of advanced adenocarcinoma of the pancreas in combination with Gemcitabine
Bendamustine	2nd or subsequent line treatment of chronic lymphatic leukaemia for patients whom fludarabine combination therapy is not a therapeutic option
Bendamustine	2nd and subsequent line of treatment of mantle cell lymphoma in patients who have not received previous Bendamustine
Bevacizumab	Treatment of patients with triple negative metastatic breast cancer and/or prior Taxane therapy
Bevacizumab	2nd or 3rd line treatment of metastatic colorectal cancer in combination with standard chemotherapy in patients who have not previously received Bevacizumab
Bosutinib	Treatment of chronic phase CML refractory to Nilotinib or Dasatinib
Bosutinib	Treatment of accelerated phase CML refractory to Nilotinib or Dasatinib
Bosutinib	Treatment of accelerated phase CML where there is significant intolerance to Dasatinib and Nilotinib.
Cetuximab	3rd and subsequent line treatment of metastatic colorectal cancer as a single agent
Cetuximab	3rd and subsequent line treatment of metastatic colorectal cancer as a single agent in patients not treated to progression under NICE TA176
Dasatinib	Treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy including Imatinib
Everolimus	2nd or 3rd line treatment of metastatic renal cell carcinoma where disease has progressed on or after treatment with VEGF-targeted therapy
Lenalidomide	2nd line treatment of multiple myeloma in patients who have contraindications to the use of Bortezomib
Panitumumab	3rd and subsequent line treatment of metastatic colorectal cancer as a single agent
Panitumumab	3rd and subsequent line treatment of metastatic colorectal cancer as a single agent in patients not treated to progression under NICE TA176
Pegylated Liposomal Doxorubicin	2nd line treatment of Fibromatosis
Peptide Receptor Radionucleotide Therapy (Lutetium177 Octreotate or Yttrium90 Octreotide/Octreotate)	Treatment of advanced neuro-endocrine tumours i.e. for pNETS after Sunitinib/chemotherapy, for mid-gut carcinoid, after octreotide/somatostatin therapies.
Pomalidomide	Treatment of relapsed and refractory multiple myeloma in patients who have received at least 2 prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy
Source: National Cancer Drugs Fund List Ver 6.0

NHS England publishes information on the number of patient applications for particular drugs/indications contained on the national CDF list on a quarterly basis. This information also includes the number of applications approved through the individual CDF request process. The latest information isattached as it is too long to be included in this answer. It is also available at:

www.england.nhs.uk/ourwork/pe/cdf/ and a copy of this is also attached.

The Government is committed to the CDF and is working with NHS England and the National Institute for Health and Care Excellence on the future arrangements for the Fund.

Secondary information

Type

Written question

Reference

HL3340

Session

2015-16

Attachment

Cancer Drugs Fund List; CDF Reporting template; Patient Numbers

Subjects

Cancer Drugs Fund

Contains statistics

Yes

Link

View this Written question on www.parliament.uk